Your browser doesn't support javascript.
loading
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra, Violeta; Wang, Anderson T; Castroviejo-Bermejo, Marta; Polanska, Urszula M; Palafox, Marta; Herencia-Ropero, Andrea; Jones, Gemma N; Lai, Zhongwu; Armenia, Joshua; Michopoulos, Filippos; Llop-Guevara, Alba; Brough, Rachel; Gulati, Aditi; Pettitt, Stephen J; Bulusu, Krishna C; Nikkilä, Jenni; Wilson, Zena; Hughes, Adina; Wijnhoven, Paul W G; Ahmed, Ambar; Bruna, Alejandra; Gris-Oliver, Albert; Guzman, Marta; Rodríguez, Olga; Grueso, Judit; Arribas, Joaquin; Cortés, Javier; Saura, Cristina; Lau, Alan; Critchlow, Susan; Dougherty, Brian; Caldas, Carlos; Mills, Gordon B; Barrett, J Carl; Forment, Josep V; Cadogan, Elaine; Lord, Christopher J; Cruz, Cristina; Balmaña, Judith; O'Connor, Mark J.
Afiliación
  • Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Wang AT; CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Castroviejo-Bermejo M; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Polanska UM; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Palafox M; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Herencia-Ropero A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Jones GN; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Lai Z; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Armenia J; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Michopoulos F; AstraZeneca Oncology R&D, Waltham, Massachusetts.
  • Llop-Guevara A; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Brough R; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Gulati A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Pettitt SJ; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Bulusu KC; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Nikkilä J; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Wilson Z; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Hughes A; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Wijnhoven PWG; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Ahmed A; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Bruna A; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Gris-Oliver A; AstraZeneca Oncology R&D, Waltham, Massachusetts.
  • Guzman M; Cancer Research UK, Cambridge Institute, Cambridge, United Kingdom.
  • Rodríguez O; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Grueso J; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Arribas J; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Cortés J; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Saura C; CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Lau A; Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Critchlow S; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Dougherty B; Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Caldas C; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Mills GB; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Barrett JC; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
  • Forment JV; AstraZeneca Oncology R&D, Waltham, Massachusetts.
  • Cadogan E; Cancer Research UK, Cambridge Institute, Cambridge, United Kingdom.
  • Lord CJ; Department of Cell Development and Cancer Biology, Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon.
  • Cruz C; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Balmaña J; AstraZeneca Oncology R&D, Waltham, Massachusetts.
  • O'Connor MJ; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
Clin Cancer Res ; 28(20): 4536-4550, 2022 10 14.
Article en En | MEDLINE | ID: mdl-35921524
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antineoplásicos Tipo de estudio: Diagnostic_studies Límite: Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antineoplásicos Tipo de estudio: Diagnostic_studies Límite: Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos